Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2010 Mar 12;21(4):439–450. doi: 10.1089/hum.2009.143

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright 2010, Mary Ann Liebert, Inc.

PMC Copyright notice

FIG. 4. — Comparative study between replicating VSV-CD40L and replication-defective Ad-CD40L as intratumoral virotherapeutic agents against B16ova tumors. (a) Kaplan–Meier plot of C57BL/6 mice (n = 8 per group) bearing scB16ova tumors treated with six intratumoral injections of VSV (5 × 10⁸ PFU of VSV-GFP or VSV-CD40L) and adenovirus (1 × 10⁹ PFU of Ad-GFP or Ad-CD40L) given 1 day apart, three times per week for 2 weeks. *p < 0.05, **p < 0.01, ***p < 0.001. (b) Histologic and immune effects of intratumoral virus injections on B16ova melanoma tumors. Subcutaneous B16ova tumors were treated with three intratumoral injections of virus on days 7, 8, and 9 after tumor inoculation. Tumors were harvested on days 10 and 16, fixed in 10% neutral buffered formalin, and processed for H&E staining. The degree of cell death (areas bounded by arrows) and immune infiltration (asterisks) were scored independently by a blinded pathologist. Photos are representative of three tumors per treatment group.

FIG. 4. — Comparative study between replicating VSV-CD40L and replication-defective Ad-CD40L as intratumoral virotherapeutic agents against B16ova tumors. (a) Kaplan–Meier plot of C57BL/6 mice (n = 8 per group) bearing scB16ova tumors treated with six intratumoral injections of VSV (5 × 10⁸ PFU of VSV-GFP or VSV-CD40L) and adenovirus (1 × 10⁹ PFU of Ad-GFP or Ad-CD40L) given 1 day apart, three times per week for 2 weeks. *p < 0.05, **p < 0.01, ***p < 0.001. (b) Histologic and immune effects of intratumoral virus injections on B16ova melanoma tumors. Subcutaneous B16ova tumors were treated with three intratumoral injections of virus on days 7, 8, and 9 after tumor inoculation. Tumors were harvested on days 10 and 16, fixed in 10% neutral buffered formalin, and processed for H&E staining. The degree of cell death (areas bounded by arrows) and immune infiltration (asterisks) were scored independently by a blinded pathologist. Photos are representative of three tumors per treatment group.